You are here: Industry Insights > small cell lung cancer

News List

FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer americanpharmaceuticalreview
April 06, 2020
The Food and Drug Administration (FDA) has approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
FDA approves AstraZeneca’s Imfinzi for small cell lung cancer pharmaceutical-technology
March 31, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adults.
Imfinzi Confirmed Sustained Overall Survival Benefit in Small Cell Lung Cancer Trial americanpharmaceuticalreview
March 18, 2020
High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies confirmed a sustained.
Merck's Keytruda, up for new FDA nod, spurs lengthy responses in small cell lung cancer fiercepharma
April 02, 2019
Merck & Co. is awaiting an FDA decision for Keytruda in previously treated small cell lung cancer, and it has new numbers to boost its case.